A federal appeals court ruling today appears to have cleared the way for Minnesota Vikings tackles Kevin and Pat Williams to play the full 2009 season before returning to Hennepin County District court as early as next spring for a civil trial over their alleged use of a substance that can be used to mask steroids.
A three-judge panel of the Eighth U.S. Circuit Court of Appeals issued a decision affirming earlier rejections of the NFL's argument that federal courts have jurisdiction over the labor laws that govern its drug-testing program.
The league suspended the players for four games each late last year for taking bumetanide, a diuretic that can be used as a masking agent for steroids.
It was an unlisted ingredient in the over-the-counter supplement StarCaps, a weight-loss supplement. StarCaps was pulled off the market earlier this year after the Food and Drug Administration learned it contained bumetanide. The Williamses, who are not related, both said they didn't know StarCaps had the banned substance. Neither player tested positive for steroids.
The two star defensive tackles, known as the "Williams Wall," are considered significant to the team's defense and Super Bowl hopes.
Today's decision essentially allows the Williamses to play while keeping the remains of the case in Hennepin County, where Judge Gary Larson already has said he likely wouldn't force the players into a civil trial during the coming season. He also had delayed action in his courtroom until the federal court determined whether it has jurisdiction over some of the claims. Now the court has said it does not.
The Williamses responded to their suspensions by filing a lawsuit in state court contending that the NFL's drug-testing procedures violate Minnesota workplace laws, and they asked that a judge void their suspensions. Then the NFL Players Association sued in U.S. District Court on their behalf.
The NFL's attorneys argued that the state claims should be dismissed because the federal courts have jurisdiction over the labor laws that govern its drug-testing program. U.S. District Judge Paul Magnuson of St. Paul and now the appellate court disagreed.